Efectos de la glicina sobre los trastornos de conducción del nervio auditivo en pacientes diabéticos tipo 2 con otoneuropatía

• MARÍA DE LOURDES MUÑOZ-CARLIN ^[1] ; JOSÉ RAYMUNDO RODRÍGUEZ-MOCTEZUMA ^[2] ; JUAN GERARDO GÓMEZ LATORRE ^[3] ; MARÍA LUISA MONTES-CASTILLO ^[4] ; SALVADOR JUÁREZ-ADAUTA ^[1]
  1. [1] Hospital General Regional 72
  2. [2] Delegación Oriente Estado de México
  3. [3] Hospital General Regional 72 Departamento de Cirugía General
  4. [4] Hospital Magdalena de las Salinas

  Mostrar afiliaciones +
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 138, Nº. 10, 2010, págs. 1246-1252
• Idioma: español
• Títulos paralelos:
  • Effects of glycine on auditory evoked potentials among diabetic patients with auditory pathway neuropathy
• Enlaces
  • Texto completo
• Resumen

  • Background: Glycine inhibits the formation of advanced glycation end products that may cause central and peripheral neuronal damage, affecting also the auditory nerve. Aim: To evaluate the effect of glycine on auditory nerve conduction and hearing level among patients with type 2 diabetes mellitus and auditory neuropathy. Material and Methods: Twenty grams of oral glycine per day were administered during 6 months to 28 type 2 diabetic patients aged 58 ± 6 years, with auditory pathway neuropathy. Hearing tests and evoked otoacustic potentials were performed regularly. Fifteen diabetic patients aged 49 ± 8 years, without auditory nerve neuropathy did not receive glycine and were followed as a control group. Results: Among patients receiving glycine, a significant improvement in left ear audiometry at 125, 250 and 500 Hz and right ear audiometry at 500 Hz, was observed. Waves I, III and V (p= 0.02) of evoked otoacustic potentials improved significantly in the left ear and wave I in the right ear. Among controls, waves V and III of evoked otoacoustic potentials had a significant impairment in the left ear. Conclusions: There was an improvement in auditory evoked potentials in patients receiving glycine and an impairment in untreated control patients.